
维布妥昔单抗治疗复发或难治性经典型霍奇金淋巴瘤的快速卫生技术评估
A rapid health technology assessment of brentuximab vedotin in therapy for relapse and refractory classic Hodgkin lymphoma
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 |
|
〉 |